December 13, 2023
GlaxoSmithKline said on December 12 that it has filed a regulatory application in Japan seeking an additional indication of its respiratory syncytial virus (RSV) vaccine Arexvy for the prevention of RSV disease in adults aged 50-59 at increased risk. In...read more